CN112807325A - 用于治疗自身消化的组合物 - Google Patents
用于治疗自身消化的组合物 Download PDFInfo
- Publication number
- CN112807325A CN112807325A CN202110088873.2A CN202110088873A CN112807325A CN 112807325 A CN112807325 A CN 112807325A CN 202110088873 A CN202110088873 A CN 202110088873A CN 112807325 A CN112807325 A CN 112807325A
- Authority
- CN
- China
- Prior art keywords
- peg
- glucose
- shock
- tranexamic acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 314
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 93
- 239000008103 glucose Substances 0.000 claims abstract description 93
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 88
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 88
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims abstract description 63
- 230000035939 shock Effects 0.000 claims abstract description 61
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 59
- 239000003792 electrolyte Substances 0.000 claims abstract description 45
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 208000010718 Multiple Organ Failure Diseases 0.000 claims abstract description 13
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims abstract description 13
- 206010058558 Hypoperfusion Diseases 0.000 claims abstract description 12
- 208000034486 Multi-organ failure Diseases 0.000 claims abstract description 12
- 206010022680 Intestinal ischaemia Diseases 0.000 claims abstract description 7
- 210000001072 colon Anatomy 0.000 claims abstract description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 68
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 64
- 239000007864 aqueous solution Substances 0.000 claims description 63
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 34
- 235000011164 potassium chloride Nutrition 0.000 claims description 34
- 239000001103 potassium chloride Substances 0.000 claims description 34
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 34
- 235000011152 sodium sulphate Nutrition 0.000 claims description 34
- 239000011780 sodium chloride Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 19
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 18
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 18
- 206010040070 Septic Shock Diseases 0.000 claims description 11
- 230000036303 septic shock Effects 0.000 claims description 10
- 230000002008 hemorrhagic effect Effects 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 7
- 206010007625 cardiogenic shock Diseases 0.000 claims description 7
- 238000013130 cardiovascular surgery Methods 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 241001115402 Ebolavirus Species 0.000 claims description 2
- ONGZMKPEWCAXFS-UHFFFAOYSA-L [Cl+].[Cl-].[K+].[Cl-] Chemical compound [Cl+].[Cl-].[K+].[Cl-] ONGZMKPEWCAXFS-UHFFFAOYSA-L 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 abstract description 10
- 238000009472 formulation Methods 0.000 description 98
- 241000700159 Rattus Species 0.000 description 65
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 34
- 230000000052 comparative effect Effects 0.000 description 31
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 24
- 210000000813 small intestine Anatomy 0.000 description 18
- 230000006698 induction Effects 0.000 description 17
- 235000017557 sodium bicarbonate Nutrition 0.000 description 17
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 17
- 210000002175 goblet cell Anatomy 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 230000000112 colonic effect Effects 0.000 description 15
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000006378 damage Effects 0.000 description 12
- 206010002091 Anaesthesia Diseases 0.000 description 11
- 230000037005 anaesthesia Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 210000000936 intestine Anatomy 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 229960003299 ketamine Drugs 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000001010 compromised effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 210000004013 groin Anatomy 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 210000001363 mesenteric artery superior Anatomy 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 4
- 229960001600 xylazine Drugs 0.000 description 4
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 3
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 3
- 206010021138 Hypovolaemic shock Diseases 0.000 description 3
- 229920000153 Povidone-iodine Polymers 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000004706 cardiovascular dysfunction Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 238000012735 histological processing Methods 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 230000004768 organ dysfunction Effects 0.000 description 3
- 210000004303 peritoneum Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229960001621 povidone-iodine Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012959 renal replacement therapy Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 206010040560 shock Diseases 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000005980 lung dysfunction Effects 0.000 description 2
- 238000005399 mechanical ventilation Methods 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058119 Neurogenic shock Diseases 0.000 description 1
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461970247P | 2014-03-25 | 2014-03-25 | |
| US61/970,247 | 2014-03-25 | ||
| US201462019007P | 2014-06-30 | 2014-06-30 | |
| US62/019,007 | 2014-06-30 | ||
| CN201580020501.9A CN106572987B (zh) | 2014-03-25 | 2015-03-24 | 用于治疗自身消化的组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580020501.9A Division CN106572987B (zh) | 2014-03-25 | 2015-03-24 | 用于治疗自身消化的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112807325A true CN112807325A (zh) | 2021-05-18 |
Family
ID=54188811
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110088873.2A Pending CN112807325A (zh) | 2014-03-25 | 2015-03-24 | 用于治疗自身消化的组合物 |
| CN202110088870.9A Active CN112641771B (zh) | 2014-03-25 | 2015-03-24 | 用于治疗自身消化的组合物 |
| CN201580020501.9A Active CN106572987B (zh) | 2014-03-25 | 2015-03-24 | 用于治疗自身消化的组合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110088870.9A Active CN112641771B (zh) | 2014-03-25 | 2015-03-24 | 用于治疗自身消化的组合物 |
| CN201580020501.9A Active CN106572987B (zh) | 2014-03-25 | 2015-03-24 | 用于治疗自身消化的组合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9314442B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3122349B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6648106B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102397379B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN112807325A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015236283B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2942358C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3122349T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2906262T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX376176B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3122349T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3122349T (cg-RX-API-DMAC7.html) |
| TW (2) | TWI669114B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015148474A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2624823A4 (en) | 2010-09-23 | 2016-08-03 | Inflammagen | ADMINISTRATION OF SERIN PROTEASE INHIBITORS IN THE STOMACH |
| CA2942358C (en) | 2014-03-25 | 2023-03-28 | Leading BioSciences, Inc. | Compositions for the treatment of autodigestion |
| CA3010986A1 (en) | 2016-01-11 | 2017-07-20 | Leading BioSciences, Inc. | Compositions and methods for treating and preventing adhesions and ileus |
| US20200323803A1 (en) * | 2017-10-24 | 2020-10-15 | Leading BioSciences, Inc. | Compositions and methods for glucose control |
| US11666532B2 (en) | 2018-01-19 | 2023-06-06 | Hyloris Developments Sa | Tranexamic acid oral solution |
| CN110730413A (zh) * | 2018-06-29 | 2020-01-24 | 阿里巴巴集团控股有限公司 | 一种终端定位方法和装置 |
| US10980757B2 (en) | 2018-09-06 | 2021-04-20 | RTU Pharma SA | Ready-to-use tranexamic acid intravenous solution |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56158707A (en) | 1980-04-08 | 1981-12-07 | Lion Corp | Composition for oral use |
| JP3496158B2 (ja) | 1993-01-26 | 2004-02-09 | 東洋カプセル株式会社 | トラネキサム酸配合ゼラチンカプセル製剤 |
| US5578568A (en) | 1994-04-22 | 1996-11-26 | Xoma Corporation | Method of treating conditions associated with intestinal ischemia/reperfusion |
| DE19617369A1 (de) | 1996-04-30 | 1997-11-06 | Immuno Ag | Lagerstabile Fibrinogen-Präparate |
| JP3940209B2 (ja) | 1996-11-14 | 2007-07-04 | 株式会社資生堂 | 可溶化化粧料 |
| US6121232A (en) | 1997-01-31 | 2000-09-19 | Omrix Biopharmaceuticals Sa | Stabilized mixture comprising fibrinogen |
| AU9027298A (en) | 1997-08-20 | 1999-03-08 | Lxr Biotechnology Inc. | Compositions containing polyethylene glycol and uses thereof |
| TWI243687B (en) | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| DE10025001A1 (de) | 2000-05-22 | 2001-11-29 | Aventis Behring Gmbh | Gewebekleber mit verbesserten anti-adhäsiven Eigenschaften |
| US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
| WO2001037854A1 (en) | 1999-11-24 | 2001-05-31 | The Regents Of The University Of California | Method for treatment and prevention of physiological shock |
| US6708822B1 (en) | 1999-11-30 | 2004-03-23 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
| US20030144212A1 (en) | 2000-07-06 | 2003-07-31 | Hoffman Keith B | Use of serine protease inhibitors to inhibit pathophysiology and neuropathology in a host |
| JP4044748B2 (ja) | 2001-10-17 | 2008-02-06 | サンスター株式会社 | 口腔用液体組成物 |
| US20040018984A1 (en) | 2002-07-17 | 2004-01-29 | Mizuo Miyazaki | Methods for preventing adhesion formation using protease inhibitors |
| GB0224909D0 (en) | 2002-10-25 | 2002-12-04 | Norgine Europe Bv | Colon cleansing compositions |
| ATE544354T1 (de) | 2002-11-26 | 2012-02-15 | Univ Chicago | Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen |
| US20050025825A1 (en) * | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
| JP2005068076A (ja) | 2003-08-25 | 2005-03-17 | Tendou Seiyaku Kk | トラネキサム酸類を含む外用液剤および清拭剤 |
| US20090215898A1 (en) | 2004-03-04 | 2009-08-27 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations |
| JP2007533755A (ja) | 2004-04-20 | 2007-11-22 | ザ ユニヴァーシティ オヴ シカゴ | 高分子量ｐｅｇ様化合物を含む治療薬送達システム |
| US20080194611A1 (en) | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
| AU2006255274A1 (en) | 2005-06-03 | 2006-12-14 | The University Of Chicago | Modulation of microbial pathogen-host cell interactions |
| CA2609985A1 (en) | 2005-06-03 | 2007-05-10 | The University Of Chicago | Modulation of cell barrier dysfunction |
| US20090186949A1 (en) | 2006-02-28 | 2009-07-23 | The University Of Chicago | Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds |
| JP5465824B2 (ja) | 2006-03-24 | 2014-04-09 | 第一三共ヘルスケア株式会社 | 医薬用製剤およびその製造方法 |
| WO2008103767A1 (en) | 2007-02-20 | 2008-08-28 | The Regents Of The University Of California | Treatment of conditions related to shock |
| US8252302B2 (en) | 2007-06-11 | 2012-08-28 | Edge Therapeutics, Inc. | Methods and compositions to treat hemorrhagic conditions of the brain |
| JP5093841B2 (ja) | 2007-07-12 | 2012-12-12 | 株式会社 資生堂 | 不織布含浸化粧料 |
| WO2009045543A1 (en) | 2007-10-04 | 2009-04-09 | The Regents Of The University Of California | Treatment of conditions related to shock |
| WO2010087874A1 (en) | 2009-01-28 | 2010-08-05 | Anazyme, Llc | Compositions and methods for diagnosis of shock |
| WO2009132149A2 (en) | 2008-04-22 | 2009-10-29 | The Regents Of The University Of California | Treatment of conditions related to cecal ligation shock |
| HRP20140939T1 (hr) | 2008-05-07 | 2014-11-21 | Salix Pharmaceuticals, Ltd. | Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva |
| US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| ZA201107285B (en) | 2009-03-06 | 2012-12-27 | Delivtx Inc | Microencapsulated bioactive agents for oral delivery and methods of the thereof |
| MX2011009988A (es) | 2009-03-23 | 2011-11-18 | Univ Chicago | Metodos para la prevencion y el tratamiento de trastornos epiteliales inducidos por radiaciones. |
| EP2464413B1 (en) * | 2009-08-12 | 2013-10-16 | Medimetrics Personalized Drug Delivery B.V. | Medicine reservoir for drug delivery device |
| WO2011028234A1 (en) | 2009-09-04 | 2011-03-10 | Xenoport, Inc. | Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid |
| EP2624823A4 (en) | 2010-09-23 | 2016-08-03 | Inflammagen | ADMINISTRATION OF SERIN PROTEASE INHIBITORS IN THE STOMACH |
| US9295715B2 (en) | 2010-10-02 | 2016-03-29 | The Regents Of The University Of California | Minimizing intestinal dysfunction |
| JP6148454B2 (ja) * | 2011-11-11 | 2017-06-14 | ロート製薬株式会社 | トラネキサム酸を含む外用及び内服用組成物 |
| ES2375784B1 (es) | 2011-12-22 | 2013-01-24 | Laboratorios Kin S.A. | Gel de ácido tranexámico |
| CN103565743B (zh) | 2012-07-23 | 2016-06-22 | 上海市徐汇区中心医院 | 氨甲环酸皮肤外用纳米制剂及其制备方法和用途 |
| WO2014028052A1 (en) | 2012-08-17 | 2014-02-20 | The University Of Chicago | Materials and methods for preventing and treating anastomotic leaks |
| CN103054861A (zh) * | 2012-12-29 | 2013-04-24 | 北京阜康仁生物制药科技有限公司 | 一种含氨甲环酸的复方固体制剂 |
| US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| CA2942358C (en) | 2014-03-25 | 2023-03-28 | Leading BioSciences, Inc. | Compositions for the treatment of autodigestion |
| US20150297619A1 (en) | 2014-04-17 | 2015-10-22 | The Regents Of The University Of California | Methods and compositions for preserving the mucosal barrier |
-
2015
- 2015-03-24 CA CA2942358A patent/CA2942358C/en active Active
- 2015-03-24 CN CN202110088873.2A patent/CN112807325A/zh active Pending
- 2015-03-24 US US14/666,926 patent/US9314442B2/en active Active
- 2015-03-24 CN CN202110088870.9A patent/CN112641771B/zh active Active
- 2015-03-24 MX MX2016012248A patent/MX376176B/es active IP Right Grant
- 2015-03-24 KR KR1020167027915A patent/KR102397379B1/ko not_active Expired - Fee Related
- 2015-03-24 PL PL15767838T patent/PL3122349T3/pl unknown
- 2015-03-24 ES ES15767838T patent/ES2906262T3/es active Active
- 2015-03-24 WO PCT/US2015/022198 patent/WO2015148474A1/en not_active Ceased
- 2015-03-24 AU AU2015236283A patent/AU2015236283B2/en not_active Ceased
- 2015-03-24 DK DK15767838.4T patent/DK3122349T3/da active
- 2015-03-24 CN CN201580020501.9A patent/CN106572987B/zh active Active
- 2015-03-24 KR KR1020227015575A patent/KR20220068266A/ko not_active Ceased
- 2015-03-24 EP EP15767838.4A patent/EP3122349B1/en active Active
- 2015-03-24 JP JP2017502766A patent/JP6648106B2/ja not_active Expired - Fee Related
- 2015-03-24 PT PT157678384T patent/PT3122349T/pt unknown
- 2015-03-25 TW TW105125832A patent/TWI669114B/zh not_active IP Right Cessation
- 2015-03-25 TW TW104109588A patent/TWI554269B/zh not_active IP Right Cessation
-
2016
- 2016-03-14 US US15/069,860 patent/US9775821B2/en not_active Expired - Fee Related
-
2017
- 2017-09-18 US US15/707,943 patent/US11123317B2/en not_active Expired - Fee Related
-
2021
- 2021-08-28 US US17/460,184 patent/US20220054439A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106572987B (zh) | 用于治疗自身消化的组合物 | |
| AU2022204450B2 (en) | Uses of oxygenated cholesterol sulfates (OCS) | |
| KR20190035776A (ko) | 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물 | |
| US20210046025A1 (en) | Injection for Protecting Ischemic Myocardium and Preparation Method thereof | |
| HK40051381A (en) | Compositions for the treatment of autodigestion | |
| HK40049334A (en) | Compositions for the treatment of autodigestion | |
| HK40049334B (en) | Compositions for the treatment of autodigestion | |
| Xudoyberdiyeva | PHARMACOKINETICS AND ITS BASICS AND DELIVERY OF DRUGS WAYS AND EFFECTS | |
| Mamajonova | PHARMACOKINETICS AND ITS BASICS AND DELIVERY OF DRUGS WAYS AND EFFECTS | |
| Wolfe et al. | Outpatient laparoscopic liver biopsy: A safe procedure | |
| CN110585210A (zh) | 三棱素a在制备抗缺血性脑卒中的药物方面的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40051381 Country of ref document: HK |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 201203 building 10, No. 860, Xinyang Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai Applicant after: Hengyi biomedicine (Shanghai) Co.,Ltd. Address before: Room 413, building 3, 1690 Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203 Applicant before: Hengyi biomedical technology (Shanghai) Co.,Ltd. |